NCT03585296View on ClinicalTrials.gov

A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

April 25, 2019

Study Completion Date

April 25, 2019

Conditions
Atopic Dermatitis
Interventions
DRUG

ATI-502

Topical Solution

Trial Locations (6)

43209

Aclaris Investigational Site, Bexley

55432

Aclaris Investigator Site, Fridley

78759

Aclaris Investigator Site, Austin

92024

Aclaris Investigational Site, Encinitas

92123

Aclaris Investigator Site, San Diego

97223

Aclaris Investigational Site, Portland

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY

NCT03585296 - A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis | Biotech Hunter | Biotech Hunter